Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Next Previous
Trial Profile

An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DASCERN
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 13 Dec 2022 Results(data cutoff, April 24, 2022; n=260; 5-Year Results) assessing safety and efficacy of Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib in Patients with Chronic Myeloid Leukemia safety presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 19 May 2022 This trial has been completed in Poland (end date: 12 Apr 2022), according to European Clinical Trials Database record.
  • 14 May 2022 This trial has been completed in Czechia (end date: 12 Apr 2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top